Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 29, 2015 10:52 PM ET

Biotechnology

Company Overview of APT Therapeutics, Inc.

Company Overview

APT Therapeutics, Inc., a development stage biotechnology drug discovery company, engages in the study of the function and expression of proteins to understand disease mechanisms at the protein, cell, and cell pathway levels. It uses a protein engineering, protein informatics, and cheminformatics software to create base therapeutics and small molecule drugs; and a drug development platform to develop anti-thrombotic therapeutic proteins to be used in stroke, percutaneous coronary intervention, and acute coronary syndrome. The company develops a method to assign biochemical function based on protein evolution, protein structure-function, and enzyme mechanism and catalysis. Its protein informa...

893 North Warson Road

St. Louis, MO 63141

United States

Founded in 2001

Phone:

314-812-8114

Fax:

314-812-8127

Key Executives for APT Therapeutics, Inc.

Chief Executive Officer, President and Director
Age: 57
Founder, Chief Scientific Officer and Director
Co-Founder and Director of Protein Engineering
Head of Legal & Regulatory Affairs
Head of Computational Drug Design
Compensation as of Fiscal Year 2015.

APT Therapeutics, Inc. Key Developments

APT Therapeutics, Inc. Develops Investigational New Drug, APT102, for Heart Attack and Stroke Patients

APT Therapeutics, Inc. is developing an investigational new drug, APT102, for heart attack and stroke patients. According to a recent study published in Science Translational Medicine, APT102 maintained optimal blood flow and reduced damage to the heart muscle by 80% in animal model studies of heart attack. Drugs commonly used to prevent blood clots for heart attack and stroke patients carry a risk of serious bleeding events. In contrast, APT102 attenuated bleeding in the study. Two of company's scientists were co-authors of the study, Soon Seog Jeong, PhD, and Ridong Chen, PhD. Dr. Chen is also founder and CEO of the company.

Similar Private Companies By Industry

Company Name Region
U.S. Tissue And Cell United States
APE-BridgePath Scientific, LLC United States
Hera Testing Laboratories, Inc. United States
Vivonics, Inc. United States
Gel Med Sciences, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact APT Therapeutics, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.